Literature DB >> 25972333

Characteristics and Antibiotic Use Associated With Short-Term Risk of Clostridium difficile Infection Among Hospitalized Patients.

Sol del Mar Aldrete1, Matthew J Magee2, Rachel J Friedman-Moraco1, Austin W Chan3, Grier G Banks4, Eileen M Burd5, Colleen S Kraft6.   

Abstract

OBJECTIVES: Polymerase chain reaction (PCR) has been shown to have an excellent sensitivity and specificity for the detection of Clostridium difficile infection (CDI). Little is known about risk factors for CDI within 14 days of an initial negative test. We sought to determine the characteristics among hospitalized patients associated with risk of short-term acquisition of CDI.
METHODS: A case-control study was conducted. Cases were patients who converted from PCR negative to positive within 14 days. Each case was matched with three controls. Conditional logistic regression was used to estimate the association between patient characteristics and CDI.
RESULTS: Of the 30 patients in our study who had a positive PCR within 14 days of a first negative PCR (cases), 15 (50%) occurred within 7 days of the initial test. Cases had a higher proportion of intravenous vancomycin use in the previous 8 weeks (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.34-8.49) and were less likely to have recent antiviral agent use (OR, 0.30; 95% CI, 0.11-0.83) compared with controls.
CONCLUSIONS: In hospitalized patients, treatment with intravenous vancomycin within the prior 8 weeks of a first negative PCR test for C difficile is a risk factor for short-term risk for hospital-acquired CDI. Repeat testing guidelines for C difficile PCR should take into consideration patients who may be at high risk for short-term acquisition of CDI. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  CDI; Clostridium difficile; Molecular; PCR; Repeat

Mesh:

Substances:

Year:  2015        PMID: 25972333      PMCID: PMC4630028          DOI: 10.1309/AJCP9EWI6QPVTPQY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  35 in total

1.  Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak.

Authors:  A Thibault; M A Miller; C Gaese
Journal:  Infect Control Hosp Epidemiol       Date:  1991-06       Impact factor: 3.254

2.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

3.  Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study.

Authors:  Renate J van den Berg; Norbert Vaessen; Hubert P Endtz; Tanja Schülin; Eric R van der Vorm; Ed J Kuijper
Journal:  J Med Microbiol       Date:  2007-01       Impact factor: 2.472

4.  Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding.

Authors:  D Z Bliss; S Johnson; K Savik; C R Clabots; K Willard; D N Gerding
Journal:  Ann Intern Med       Date:  1998-12-15       Impact factor: 25.391

5.  Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation.

Authors:  S Bilgrami; J M Feingold; D Dorsky; R L Edwards; R D Bona; A M Khan; F Rodriguez-Pinero; J Clive; P J Tutschka
Journal:  Bone Marrow Transplant       Date:  1999-05       Impact factor: 5.483

6.  Bacterial diarrhea in persons with HIV infection, United States, 1992-2002.

Authors:  Travis H Sanchez; John T Brooks; Patrick S Sullivan; Marta Juhasz; Eric Mintz; Mark S Dworkin; Jeffrey L Jones
Journal:  Clin Infect Dis       Date:  2005-10-31       Impact factor: 9.079

7.  Clostridium difficile colonization and diarrhea at a tertiary care hospital.

Authors:  M H Samore; P C DeGirolami; A Tlucko; D A Lichtenberg; Z A Melvin; A W Karchmer
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

Review 8.  Clostridium difficile infection associated with antineoplastic chemotherapy: a review.

Authors:  A Anand; A E Glatt
Journal:  Clin Infect Dis       Date:  1993-07       Impact factor: 9.079

9.  Risk factors for Clostridium difficile toxin-associated diarrhea.

Authors:  E Brown; G H Talbot; P Axelrod; M Provencher; C Hoegg
Journal:  Infect Control Hosp Epidemiol       Date:  1990-06       Impact factor: 3.254

10.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.

Authors:  L Clifford McDonald; Maria Owings; Daniel B Jernigan
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

View more
  4 in total

1.  Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.

Authors:  Brandon J Webb; Aruna Subramanian; Bert Lopansri; Bruce Goodman; Peter Bjorn Jones; Jeffrey Ferraro; Edward Stenehjem; Samuel M Brown
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia.

Authors:  Yilun Sun; Rachael L Huskey; Li Tang; Hiroto Inaba; Aditya H Gaur; Raul Ribeiro; Jeffrey E Rubnitz; Joshua Wolf
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Factors associated with an outbreak of hospital-onset, healthcare facility-associated Clostridium difficile infection (HO-HCFA CDI) in a Mexican tertiary care hospital: A case-control study.

Authors:  Eric Ochoa-Hein; José Sifuentes-Osornio; Alfredo Ponce de León-Garduño; Pedro Torres-González; Víctor Granados-García; Arturo Galindo-Fraga
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

4.  Clostridium difficile Infections in Medical Intensive Care Units of a Medical Center in Southern Taiwan: Variable Seasonality and Disease Severity.

Authors:  Jen-Chieh Lee; Yuan-Pin Hung; Hsiao-Ju Lin; Pei-Jane Tsai; Wen-Chien Ko
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.